Introduction
Triglyceride deposit cardiomyovasculopathy TGCV is a rare and intractable cardiovascular disease that was first reported among patients requiring cardiac transplantation in Japan 1 . TGCV is characterized by a massive accumulation of triglyceride TG in the myocardium 2 and coronary arteries 3 which leads to severe congestive heart failure and angina pectoris. TGCV is classified into primary and idiopathic types. Primary TGCV is caused by genetic mutations in PNPLA2 which encodes adipose triglyceride lipase ATGL , a rate-limiting enzyme in the hydrolysis of intracellular TG and the release of free long-chain fatty acids LCFAs 4, 5 . Idiopathic TGCV does not carry PNPLA2 mutations 6 , but is associated with a marked reduction in ATGL activity in peripheral leukocytes 7 .
Clinically, TGCV with ATGL deficiency causes severe heart failure with a poor prognosis 1, 8, 9 . Hence, the development of specific treatment for TGCV is an urgent requirement. Our previous in vitro experiments on fibroblasts derived from patients with TGCV showed that LCFAs, the major energy source for the normal heart, accumulate as TG in cytoplasmic lipid droplets owing to ATGL deficiency 10, 11 . To resolve the above-mentioned toxicity of LCFAs, we explored the development of nutritional therapeutic agents from medium-chain fatty acids MCFAs for the following reasons: 1 MCFAs have a long and safe history as they have been used clinically for 50 years in patients with metabolic and neurological disorders 12 14 ; 2
MCFAs are an alternative energy source to LCFA and glucose 15, 16 ; and 3 the intracellular metabolism of MCFAs was shown to be different from that of LCFAs 17 . It was shown that MCFAs activated FA oxidation enzymes in the rat liver when oils containing medium-chain triglycerides MCTs were administered orally to rats 18 . Moreover, the effects of MCTs on body fat have been evaluated and it was suggested that an MCT diet reduced body weight in humans 19, 20 .
Previous studies have shown that TG deposition in cardiomyocytes in Atgl KO mice resulted in cardiac phenotypes that were similar to those observed in patients with TGCV 5, 10 . In the present study, the potential beneficial effects of tricaprin, the TG form of capric acid a type of MCFA on the cardiac TG deposition and dysfunctions were examined in Atgl KO mice. Wild-type WT C57Bl/6 mice fed the tricaprin diet were used as the control.
Animal experiments
All analyses described in this section were performed on 7-week-old Atgl KO mice, because the KO mice over 8 weeks of age could not tolerate anesthesia owing to heart failure. 2.3.1 Myocardial iodine-123-β methyl iodophenyl-pentadecanoic acid BMIPP scintigraphy by single-photon emission computed tomography BMIPP-SPECT LCFA clearance at the cellular level can be detected by in vivo myocardial scintigraphy using BMIPP, a radiolabeled analog of LCFA 22 24 . We recently reported that patients with TGCV showed a defective washout of BMIPP in a scintigraphic analysis 2 . To evaluate LCFA metabolism in the heart of Atgl KO mice in this study, BMIPP-SPECT was used. The Atgl KO mice fed the tricaprin or tricaprin diet n 4 in each group were evaluated by using myocardial BMIPP-SPECT. BMIPP was obtained from Nihon Medi-Physics Co. Ltd., Tokyo, Japan, and injected into the jugular vein of mice under isoflurane anesthesia. BMIPP was then traced by SPECT/CT Flex X-SPECT/CT, Gamma Medica-Ideas Inc., CA, USA . The SPECT images were obtained at 1 h and 4 h after the injection of BMIPP. The regions of interest ROIs were placed on the myocardium-based on CT images, and the decay-corrected radioactivity uptake in each ROI was obtained. Washout rates WORs , used to evaluate LCFA metabolism, were calculated from the formula BMIPP uptake 1 h -remaining BMIPP 4 h / BMIPP uptake 1 h . 2.3.2 Measurements of myocardial lipid deposition and left ventricular ejection fraction LVEF by CT Micro-CT has been used to measure cardiac function in rodents 25, 26 . In the present experiment, micro-CT Latheta LCT-200, Hitachi-Aloka Medical, Tokyo, Japan was used to measure cardiac lipid deposition and function in the mouse heart. The myocardial lipid deposition was examined in KO mice fed the tricaprin or tricaprin diet n 5 in each group . The CT values in Hounsfield units, HU were measured in four regions the septum and the anterior, posterior, and lateral walls of the heart and the mean CT value was calculated from the CT values of four points.
The KO mice that were fed the tricaprin or tricaprin diet n 7 in each group were examined by using a previously reported method for measurement of LVEF 25 .
After the mice were anesthetized, 30 μL of contrast agent ExiTron nano 12000, Miltenyi Biotec, Germany was injected into the subclavian vein of the mice. The systolic and diastolic heart volumes were examined by using micro-CT. Images were obtained after every 96 μm, which separated the LV into segments; the volume of each segment was calculated by multiplication of the area by 96. The total LV volume was calculated from addition of all segmental volumes. LVEF was determined after the systolic and diastolic volumes of the whole heart were calculated. EF was calculated from the following formula:
where LVEDV is the LV end-diastolic volume, and LVESV is the LV end-systolic volume.
Histological analysis
The mice hearts were fixed in formalin. The paraffin block sections were stained with hematoxylin and eosin HE and Masson s trichrome, and examined by using a microscope Olympus, Tokyo, Japan .
Statistical analysis
The data are presented as the mean standard error. A p value of 0.05 was considered to indicate statistical significance.
Results

Tricaprin diet improved LCFA WOR in the heart of
Atgl KO mice Similar to that observed in patients with TGCV 2 , the WORs of BMIPP were considerably reduced in the KO mice fed the tricaprin diet Fig. 1A and 1B , In contrast, the WORs of BMIPP in KO mice fed the tricaprin diet were markedly higher than those in mice fed the tricaprin diet Fig. 1A and 1B . As BMIPP is known to be incorporated into the cytoplasmic TG pool and oxidized by the cardiac mitochondria of rodents, similar to native LCFA 27 , the increased WOR indicated that the tricaprin diet might facilitate LCFA metabolism in the heart of the KO mice.
Tricaprin diet ameliorated lipid accumulation in the
heart of Atgl KO mice The myocardial CT values shown in Fig. 2A and 2B reflective of the tissue TG content in patients with TGCV 6, 9 .
The CT value in the WT group was 125 9.6 HU. In contrast, the CT values of the KO mice fed the tricaprin diet were low. The tricaprin diet-fed group showed significantly higher CT values than the tricaprin diet-fed group 27.5 5.7 HU vs. 8.1 5.5 HU, *p 0.01 Fig.  2B . This suggested that the tricaprin diet reduced fat accumulation in the heart of Atgl KO mice.
Histological analysis was performed to confirm the observations obtained by using micro-CT. In 7-week-old KO mice, massive vacuoles were present in cardiomyocyte and fibrotic changes were observed after Masson s trichrome staining Fig. 2C , as shown in previous results 5 . These features were attenuated in KO mice fed the tricaprin diet c and f in Fig. 2C .
3.3
Tricaprin diet improved LV function in the heart of Atgl KO mice We assessed the effect of the tricaprin diet on cardiac function Fig. 3 . The LVEF in the KO mice fed the tricaprin diet was significantly higher than that in the KO mice fed the tricaprin diet 30 12 vs. 15 9 , p 0.01 . LVEF in the KO mice fed the tricaprin diet was comparable with that of WT mice fed tricaprin diet, which indicated that LV function was restored in the KO mice fed the tricaprin diet.
Discussion
There are several hypotheses that may explain the beneficial effects of the tricaprin diet in ATGL-deficient conditions. First, capric acid can be used and oxidized as an alternative energy source, as reported in patients with other rare genetic disorders, such as very long-chain acylCoA dehydrogenase and malonyl-CoA decarboxylase deficiencies; in contrast, very long chain fatty acils and LCFAs, respectively, cannot be metabolized owing to defects in the corresponding enzymes 28, 29 . Second, capric acid might facilitate TG hydrolysis via certain MCFA-specific pathways at the cellular level, as previously suggested by a detailed biochemical analysis 17 . Third, the tricaprin diet contains relatively low 2 natural fat, and it is potentially, not tricaprin, but the low natural fat content, that contributes to the present observations; however, this is unlikely, because a low-fat diet paradoxically induced fat accumulation 30 and shortened the life span of Atgl KO mice data not shown . Capric acid has been reported to increase the capacity for fatty acid oxidation in mouse skeletal muscle 31 , and reduce the body weight of high-fat diet-fed mice through an increase in ATGL level 32 .
This study has certain limitations. First, MCFAs include caprylic acid, capric acid and lauric acid. We examined the beneficial effects of capric acid on mouse cardiac functions; however, other MCFAs such as caprylic acid and lauric acid may have similar effects that are not examined in the study. Second, the detailed molecular mechanisms of the capric acid-mediated improvement in LCFA metabolism were not clarified in this study.
Conclusion
In summary, the tricaprin diet improved the myocar-dial metabolism of LCFAs, reduced myocardial lipid deposition Fig. 4 , and improved left ventricular function in a mouse model of TGCV. We believe that the present data are sufficient to translate the use of tricaprin into clinical trials as nutritional therapeutic agents for patients with severe and critical symptoms of TGCV. diet-fed group improved after feeding the mice tricaprin diet. *p 0.01 . C Representative images of HE staining in the hearts of WT mice that were fed tricaprin diet a , and KO mice that were fed tricaprin diet b or tricaprin diet c . Masson s trichrome staining is also shown in d-f . More lipid accumulation and fibrotic changes are observed in KO mice that were fed tricaprin diet b and e . However, these are attenuated in KO mice that were fed tricaprin diet c and f . Scale bar 100 μm. Red and blue bars indicate segmental LV volumes at end-systole and end-diastole, respectively, in A WT mice that were fed tricaprin diet , B KO mice that were fed tricaprin diet , and C KO mice that were fed tricaprin diet . D The mean value of LVEF in KO mice that were fed tricaprin diet was significantly higher than that in mice fed tricaprin diet p 0.01 n 7 for each group . 
